1
|
Sakineh A, Noorbakhsh MF, Ahmadi N, Saeed N, Behdokht B. Evaluation of the Protective Effect of Citral, Silymarin, and Thymoquinone on Methotrexate-Induced Lung Injury in Rats. J Pharmacopuncture 2023; 26:184-191. [PMID: 37405117 PMCID: PMC10315881 DOI: 10.3831/kpi.2023.26.2.184] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2023] [Revised: 03/08/2023] [Accepted: 05/02/2023] [Indexed: 07/06/2023] Open
Abstract
Objectives Several studies have reported that methotrexate is an anti-cancer and immunosuppressive drug leading to lung injury. Therefore, the present study aimed to investigate the protective effects of silymarin, citral, and thymoquinone on methotrexate-induced pulmonary toxicity. Methods Forty-eight rats were divided into six groups, including healthy, Methotrexate, and drug carrier control groups and silymarin, citral, and thymoquinone treatment groups. At the end of the experiment, the studied rats were anesthetized and sacrificed by CO2. Lung tissue samples were isolated to measure the antioxidant activity and histopathological evaluation. Results In the thymoquinone treatment group, the concentration of total antioxidant capacity and Malondialdehyde increased and decreased significantly, respectively, compared to the methotrexate group. The histopathological evaluation of the lung of the methotrexate group showed hemorrhage and congestion, the nodule-like accumulation of mononuclear inflammatory lymphocytes around the blood vessel, a small number of neutrophils around the blood vessel, and the inflammatory cells around the small vessels. However, no significant pathological alterations were observed in the treatment groups, especially the thymoquinone treatment group. Conclusion Thymoquinone has the greatest protective effect on methotrexate-induced lung injury, probably due to its antioxidant effect.
Collapse
Affiliation(s)
- Amani Sakineh
- Department of Basic Sciences, School of Veterinary Medicine, Shiraz University, Shiraz, Iran
| | | | - Nasrollah Ahmadi
- Department of Pathobiology, School of Veterinary Medicine, Shiraz University, Shiraz, Iran
| | - Nazifi Saeed
- Department of Clinical Sciences, School of Veterinary Medicine, Shiraz University, Shiraz, Iran
| | - Barzan Behdokht
- Department of Basic Sciences, School of Veterinary Medicine, Shiraz University, Shiraz, Iran
| |
Collapse
|
2
|
Methotrexate pneumonitis in a patient with gestational trophoblastic neoplasia. Afr J Thorac Crit Care Med 2022; 28:10.7196/AJTCCM.2022.v28i3.254. [PMID: 36339108 PMCID: PMC9632629 DOI: 10.7196/ajtccm.2022.v28i3.254] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/23/2022] [Indexed: 11/13/2022] Open
Abstract
Methotrexate, an immunomodulatory agent used for a wide variety of indications, can cause pulmonary toxicity in the form of pneumonitis, organising pneumonia, pulmonary fibrosis, pleural effusion, pulmonary infections or lymphoproliferative disease. We report a case of methotrexate pneumonitis in a patient with gestational trophoblastic neoplasia. The diagnosis of methotrexate pneumonitis is challenging, as the signs and symptoms can be caused by intercurrent infection, concomitant medications or an underlying disease condition. A high index of suspicion is required for diagnosis. Management consists of drug discontinuation and steroids in patients with respiratory failure.
Collapse
|
3
|
Singh C, Jain A, Takkar A, Agarwal A, Rohilla M, Lad D, Khadwal A, Basher R, Radotra BD, Bal A, Das A, Gupta V, Lal V, Varma S, Malhotra P, Prakash G. Successful Use of High Dose Methotrexate in Treatment of Primary CNS Lymphoma Patients Without Access to Serum Methotrexate Levels Monitoring: Challenges and Outcome. Indian J Hematol Blood Transfus 2022; 38:68-77. [PMID: 35125713 PMCID: PMC8804055 DOI: 10.1007/s12288-021-01438-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2021] [Accepted: 04/19/2021] [Indexed: 01/03/2023] Open
Abstract
AIMS AND OBJECTIVES High dose methotrexate (HDMTx) based chemotherapy forms the backbone of therapy for patients with Primary Central Nervous system Lymphoma (PCNSL). However, delivering HDMTx in resource constrained settings, especially without therapeutic drug monitoring, is difficult. We share our experience of treatment of patients with PCNSL at our center over a 10-year period with local adaptations made to deliver HDMTx. MATERIALS AND METHODS We retrospectively analysed the case records of patients diagnosed with a PCNSL over the course of 10 years from 2010 to 2020. RESULTS Fifty-five patients received therapy for newly diagnosed PCNSL. Thirty-six patients received Modified De-Angelis protocol ± Rituximab with curative intent. Fourteen of these patients were unable to complete the protocol with the most common cause being development of methotrexate toxicity. Patients unable to complete the designated 5 cycles of HDMTx had a poorer PS and higher probability of having a high IELSG score at baseline. Nineteen patients were given non HDMTx based therapy either due to advanced age or poor performance status. Twenty-nine patients (52.7%) were able to achieve a complete response. The most common cause of mortality was relapse/progressive disease. The Median EFS and OS of the cohort was 29 months and 40 months respectively. CONCLUSION All attempts should be made to have therapeutic drug level monitoring for administration of HDMTX based therapy for the patients with PCNSL, more so in patients who have poor performance status and a high IELSG score. If it is imperative to give HDMTx without access to TDM facility then a possible risk of higher toxicity should be explained to all patients, beforehand.
Collapse
Affiliation(s)
- Charanpreet Singh
- Clinical Hematology and BMT Division, Department of Internal Medicine, Nehru Hospital, Postgraduate Institute of Medical Education and Research, F block, 4th Floor, Chandigarh, 160012 India
| | - Arihant Jain
- Clinical Hematology and BMT Division, Department of Internal Medicine, Nehru Hospital, Postgraduate Institute of Medical Education and Research, F block, 4th Floor, Chandigarh, 160012 India
| | - Aastha Takkar
- Department of Neurology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
| | - Aniruddha Agarwal
- Department of Ophthalmology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
| | - Manish Rohilla
- Department of Cytology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
| | - Deepesh Lad
- Clinical Hematology and BMT Division, Department of Internal Medicine, Nehru Hospital, Postgraduate Institute of Medical Education and Research, F block, 4th Floor, Chandigarh, 160012 India
| | - Alka Khadwal
- Clinical Hematology and BMT Division, Department of Internal Medicine, Nehru Hospital, Postgraduate Institute of Medical Education and Research, F block, 4th Floor, Chandigarh, 160012 India
| | - Rajender Basher
- Department of Nuclear Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India
| | - B. D. Radotra
- Department of Histopathology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
| | - Amanjit Bal
- Department of Histopathology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
| | - Ashim Das
- Department of Histopathology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
| | - Vishali Gupta
- Department of Ophthalmology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
| | - Vivek Lal
- Department of Neurology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
| | - Subhash Varma
- Clinical Hematology and BMT Division, Department of Internal Medicine, Nehru Hospital, Postgraduate Institute of Medical Education and Research, F block, 4th Floor, Chandigarh, 160012 India
| | - Pankaj Malhotra
- Clinical Hematology and BMT Division, Department of Internal Medicine, Nehru Hospital, Postgraduate Institute of Medical Education and Research, F block, 4th Floor, Chandigarh, 160012 India
| | - Gaurav Prakash
- Clinical Hematology and BMT Division, Department of Internal Medicine, Nehru Hospital, Postgraduate Institute of Medical Education and Research, F block, 4th Floor, Chandigarh, 160012 India
| |
Collapse
|
6
|
Fikry EM, Hassan WA, Gad AM. Bone marrow and adipose mesenchymal stem cells attenuate cardiac fibrosis induced by methotrexate in rats. J Biochem Mol Toxicol 2017; 31. [PMID: 28815865 DOI: 10.1002/jbt.21970] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2017] [Revised: 07/16/2017] [Accepted: 07/20/2017] [Indexed: 02/05/2023]
Abstract
Mesenchymal stem cells (MSCs) are an ideal adult stem cell with capacity for self-renewal and differentiation with an extensive tissue distribution. The present study evaluates the therapeutic effects of bone marrow mesenchymal stem cells (BM-MSCs) or adipose-derived mesenchymal stem cells (AD-MSCs) against the development of methotrexate (MTX)-induced cardiac fibrosis versus dexamethasone (DEX). Rats were allocated into five groups; group 1, received normal saline orally; group 2, received MTX (14 mg/kg/week for 2 weeks); groups 3 and 4, treated once with 2 × 106 cells of MTX + BM-MSCs and MTX + AD-MSCs, respectively; and group 5, MTX + DEX (0.5 mg/kg, for 7 days, P.O.). MTX induced cardiac fibrosis as marked changes in oxidative biomarkers and elevation of triglyceride, cholesterol, aspartate aminotransferase, gamma-glutamyl transferase, creatine kinase, and caspase-3, as well as deposited collagen. These injurious effects were antagonized after treatment with MSCs. So, MSCs possessed antioxidant, antiapoptotic, as well antifibrotic effects, which will perhaps initiate them as notable prospective for the treatment of cardiac fibrosis.
Collapse
Affiliation(s)
- Ebtehal Mohammad Fikry
- Department of Pharmacology, National Organization for Drug Control and Research, NODCAR, Giza, Egypt
| | - Wedad A Hassan
- Department of Pharmacology, National Organization for Drug Control and Research, NODCAR, Giza, Egypt
| | - Amany M Gad
- Department of Pharmacology, National Organization for Drug Control and Research, NODCAR, Giza, Egypt
| |
Collapse
|
7
|
Fikry EM, Safar MM, Hasan WA, Fawzy HM, El-Denshary EEDS. Bone Marrow and Adipose-Derived Mesenchymal Stem Cells Alleviate Methotrexate-Induced Pulmonary Fibrosis in Rat: Comparison with Dexamethasone. J Biochem Mol Toxicol 2015; 29:321-9. [DOI: 10.1002/jbt.21701] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2015] [Revised: 03/03/2015] [Accepted: 03/10/2015] [Indexed: 12/25/2022]
Affiliation(s)
- Ebtehal M. Fikry
- Department of Pharmacology; National Organization for Drug Control and Research; NODCAR Giza Egypt
| | - Marwa M. Safar
- Department of Pharmacology & Toxicology Faculty of Pharmacy; Cairo University; Cairo Egypt
| | - Wedad A. Hasan
- Department of Pharmacology; National Organization for Drug Control and Research; NODCAR Giza Egypt
| | - Hala M. Fawzy
- Department of Pharmacology; National Organization for Drug Control and Research; NODCAR Giza Egypt
| | | |
Collapse
|
8
|
Yadav BS, Bansal A, Sharma SC, Malhotra P, Ghosh N, Holdhoff M, Shustov A, Chamberlain M, Newton H, Kumethkar P, Raizer JN, Glass J, Morris GJ. A 60-year-old Indian male with altered sensorium and extensive lymphoma of the scalp. Semin Oncol 2013; 40:e9-21. [PMID: 23806503 DOI: 10.1053/j.seminoncol.2013.04.014] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Budhi S Yadav
- Department of Medicine, Mount Sinai Hos- pital of Queens, Long Island City, NY 11102, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|